How Amphista Therapeutics is positioning non-cereblon degraders for next-generation oncology pipelines
Discover how Amphista Therapeutics’ SMARCA2 and TEAD degrader data could redefine targeted cancer therapies. Read the full analysis now.
Pharma & Biotech
Pharma & Biotech
What Orion Corporation’s FDA orphan designation for ODM-212 means for mesothelioma treatment innovation
Discover how Orion Corporation’s ODM-212 orphan drug status could reshape mesothelioma treatment and drive innovation in Hippo pathway targeting.